AgingResearch.NewsJoin free

Ocuphire Pharma

CompanyUnited States

Ocuphire Pharma develops one asset, in phase 2 (phentolamine mesylate in decrease in night vision). Mostly small molecule acting on ADRA2A, ADRA1A and ADRA1D; based in the United States.

1
Asset
Furthest stage
Phase 2
1
Trial
1
Signal

Pipeline

1

  • phentolamine mesylate

    Blocks alpha-adrenergic receptors in the iris, reducing pupil diameter to improve night vision.

    Phase 2, Small molecule, ADRA2A, ADRA1A, decrease in night vision, loss disturbance; vision

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Evidence behind the mechanisms5
  • Trials1
  • Signals1
  • Similar companies3

Intelligence